PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | -5.78% | +2.42% | -48.54% |
05-07 | Pavmed Inc. Appoints Dennis Matheis to Board of Directors | CI |
03-27 | Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.54% | 21.22M | |
+11.73% | 221B | |
+9.53% | 186B | |
+14.63% | 137B | |
+27.47% | 109B | |
-0.04% | 63.09B | |
+13.73% | 52.68B | |
+4.86% | 50.86B | |
+7.72% | 42.53B | |
+7.86% | 37.76B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- PAVmed Inc. announced that it has received $13.625 million in funding